Is Adderall Safe with Ketamine Therapy?

If you're on Adderall (or Vyvanse, or Ritalin, or another stimulant for ADHD) and considering at-home ketamine therapy, the combination is reasonable with a small timing rule: skip your stimulant on each ketamine session day and resume your normal schedule the next day. The longer answer involves what the pharmacology actually does, what the published literature does and doesn't say, and why the session-day hold is the cleanest operational rule we can give patients.

Why the question matters

ADHD and depression overlap substantially. Studies of treatment-resistant depression populations consistently find that 22 to 30 percent of patients also carry a current or historical ADHD diagnosis, and many of these patients are on stimulant treatment when they begin looking at ketamine therapy. So the practical question is not academic: a significant fraction of our patients arrive on Adderall, Vyvanse, or methylphenidate-class stimulants, and the right combination policy matters for both safety and treatment continuity.

The reason patients (and prescribers) raise the question is intuitive. Both stimulants and ketamine can transiently affect cardiovascular tone. Stimulants are sympathomimetic and cause measurable increases in heart rate and blood pressure during their therapeutic window. Ketamine causes transient cardiovascular effects during the acute session, including a modest rise in heart rate and blood pressure that typically peaks at 10-15 minutes after the dose and resolves within an hour. Combining the two on the same day could stack those cardiovascular loads in a way that is not therapeutically useful and might matter for patients with underlying cardiovascular risk.

The question we want to ask honestly is: is this stacking actually clinically dangerous, or is the conservatism appropriate but the underlying risk small?

What the pharmacology actually does

Stimulants like Adderall (amphetamine plus dextroamphetamine salts) work primarily by causing direct release of dopamine and norepinephrine from presynaptic neurons, with secondary effects on reuptake inhibition. The cardiovascular effects (heart rate, blood pressure, sometimes pupil dilation) are downstream of the systemic catecholamine elevation. Vyvanse (lisdexamfetamine) is a prodrug that gets enzymatically converted to dextroamphetamine in the bloodstream, producing the same active metabolite with a smoother onset and longer duration. Methylphenidate (Ritalin, Concerta) works through a different mechanism, blocking the reuptake of dopamine and norepinephrine rather than releasing them directly, but the net cardiovascular effect is similar.

Ketamine works on glutamate, not catecholamines. Its primary mechanism is NMDA receptor antagonism, which triggers a cascade of downstream effects including AMPA receptor activation and BDNF release. The transient cardiovascular effects of ketamine are thought to arise from an acute sympathomimetic response (transient catecholamine release during the dissociative experience) rather than from chronic neurotransmitter modulation.

So the two drugs do not share a primary mechanism, but they share a downstream cardiovascular endpoint: both can raise blood pressure and heart rate transiently, and combining them on the same day could stack those effects. This is the basis for the session-day hold.

What the published literature actually says

The most thorough systematic review on ketamine pharmacodynamic interactions (Veraart and colleagues, International Journal of Neuropsychopharmacology 2021, PMID 34170315) explicitly states: "No studies were found investigating the concomitant use of ketamine with psychostimulants." That sentence is worth pausing on. The Veraart review reviewed 24 studies on ketamine combined with lithium, lamotrigine, benzodiazepines, MAOIs, and various antipsychotics. They specifically looked for studies on psychostimulants, and they found zero. The literature gap itself is the citation.

This means the evidence base for the Adderall plus ketamine combination is thinner than for, say, SSRIs plus ketamine (where multiple RCTs and meta-analyses establish safety) or even MAOIs plus ketamine (where the Veraart 2022 case series provides direct safety data). For stimulants, we are reasoning from pharmacology and from clinical practice patterns rather than from a published evidence base.

The pharmacology supports a conservative posture: additive cardiovascular load is theoretically real and worth managing. The clinical practice patterns support a non-alarmist posture: stimulants are not contraindicated in any standard ketamine therapy protocol, including the rigorous Spravato (esketamine) REMS program, which specifically anticipates patients on concurrent stimulants for ADHD and incorporates pre-dose blood pressure monitoring and post-dose observation into routine care. The FDA treats this combination as manageable, not as contraindicated. The Curran 2026 Journal of Clinical Psychiatry outcomes study (N=332) and the Alnefeesi 2022 Journal of Psychiatric Research meta-analysis (2,665 patients across 79 studies, including many with ADHD comorbidity) did not flag stimulant-specific safety signals despite their populations including stimulant-prescribed patients.

So the honest summary is: pharmacologically plausible cardiovascular concern, zero documented case reports of harm, regulatory framework treats it as manageable, ADHD treatment is routinely continued during ketamine therapy in clinical practice. The session-day hold is a conservative-but-cheap operational rule that addresses the theoretical concern at near-zero cost to ADHD treatment continuity.

The Tovani session-day stimulant hold

The rule is simple: skip your Adderall (or Vyvanse, or methylphenidate-class stimulant) on the day of a planned ketamine session. Resume your normal schedule the next day.

We chose this rule (rather than a more complicated "X hours before, Y hours after" window) for three reasons.

First, the long-acting formulations make timing math impractical. Adderall XR provides therapeutic levels for 12 hours; Vyvanse provides them for 13-14 hours. "Take it 6 hours before your session" doesn't actually clear the stimulant from your system. The simplest way to ensure the cardiovascular load is not stacked on session day is to not take the stimulant on that day.

Second, the session-day hold is operationally clean and patient-friendly. One clear rule that fits on an index card is much easier to follow than a timing chart. Patient adherence to "skip Tuesday" is much higher than to "take it before 7 AM only if your session is after 7 PM, otherwise skip."

Third, the cost to ADHD treatment continuity is small. Missing one day of stimulant dosing per planned ketamine session does not produce a clinically meaningful loss of ADHD treatment effect. Most patients tolerate the off-day fine; some find that the ketamine session day is one where they're not doing demanding cognitive work anyway (rest, integration, lower-stimulation activities), so the missing stimulant matters less than it would on a typical work day.

If you have specific work or caregiving obligations on a planned session day that make missing your stimulant impractical, talk to us; we can usually reschedule the session for a different day.

Specific stimulants this rule covers

The session-day hold applies to all stimulant ADHD medications. The cardiovascular profile and timing rule are similar across the class, with minor mechanism differences:

Amphetamine-class stimulants include Adderall and Adderall XR (mixed amphetamine salts), Mydayis (extended-release amphetamine), Vyvanse (lisdexamfetamine, prodrug converted to dextroamphetamine in the bloodstream), and Dexedrine (dextroamphetamine alone). All cause direct catecholamine release. Skip on session day.

Methylphenidate-class stimulants include Ritalin and Ritalin LA (methylphenidate), Concerta (extended-release methylphenidate), Daytrana (transdermal methylphenidate patch), Quillivant XR (liquid extended-release methylphenidate), and Focalin and Focalin XR (dexmethylphenidate). All work through reuptake inhibition rather than direct release. Skip on session day; for the Daytrana patch specifically, remove it the morning of the session and reapply the next morning.

Non-stimulant ADHD medications do not require the session-day hold. Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor with a different cardiovascular profile and slow onset; it does not stack cardiovascular load with ketamine in the same way. Guanfacine (Intuniv) and clonidine (Kapvay) are alpha-2 agonists that actually lower blood pressure and have no concerning interaction with ketamine. If you're on one of these as your ADHD medication, continue your normal dosing on session days.

Special populations: cardiovascular history or very high doses

For most patients, the session-day hold is sufficient and we proceed with standard at-home onboarding. A few patient profiles warrant a slightly more detailed conversation at intake.

Patients with existing hypertension that's controlled with medication: usually proceed with standard onboarding, with confirmation that your home BP readings are stable on your current regimen.

Patients with uncontrolled hypertension: addressed at the eligibility-screening level. Uncontrolled BP is already a contraindication for at-home ketamine independent of stimulant use; resolving the BP control is the gating step.

Patients with significant cardiovascular history (prior MI, arrhythmia, cardiomyopathy, family history of sudden cardiac events at young ages): we typically ask for a current ECG and a brief letter from your cardiologist confirming that ketamine therapy is reasonable for your CV picture. The stimulant question is secondary in this conversation; the underlying cardiovascular status is primary.

Patients on very high stimulant doses (above FDA-approved daily maximums, dose-titrated up over time for severe ADHD): we have a more detailed conversation about the rationale and confirm the prescribing physician is reviewing the dose periodically. Most of these patients still proceed with standard onboarding plus the session-day hold.

The misuse question

This page is for patients on a legitimate, prescribed stimulant taken as directed for ADHD. Patients with active stimulant use disorder (using more than prescribed, using illicit Adderall not prescribed to them, or using street stimulants like cocaine or methamphetamine) are a different clinical conversation. The eligibility-screening intake asks about substance use disorder generally; honest disclosure at intake is what allows us to make the right call. If active stimulant use disorder is part of the picture, at-home ketamine is typically not the right setting, and we may refer you to a clinic-based or integrated-care program. This isn't because ketamine is universally inappropriate in stimulant use disorder; it's because at-home unmonitored isn't the setting where that combination is studied or supported.

What we do at intake

When a patient is on a stimulant, our intake process layers a few confirmations on top of standard eligibility:

The specific stimulant and formulation. We note the brand and whether it's IR, XR, or transdermal.

The total daily dose, duration of treatment, and how long you've been at the current dose. Stable on the same dose for 6+ months is the most common picture.

Any cardiovascular history: current hypertension, prior arrhythmia, prior MI, family history of sudden cardiac events, or other cardiac concerns.

Any other concurrent cardiovascular-active medications.

For patients with significant CV history or very high stimulant doses, we may ask for a current ECG before starting. Most patients don't need this.

We explain the session-day stimulant hold in writing and confirm understanding before scheduling the first session.

Bottom line

Adderall, Vyvanse, methylphenidate-class stimulants, and other prescribed stimulants combine safely with at-home ketamine therapy when the stimulant is held on each ketamine session day. The pharmacologic concern about stacking cardiovascular load is real but small at therapeutic doses, the literature has not documented case reports of harm, and clinical practice routinely continues ADHD treatment during ketamine therapy with this kind of timing rule. ADHD treatment doesn't pause for ketamine therapy; the only adjustment is one skipped dose per planned session day. Patients with significant cardiovascular history or very high stimulant doses get a more detailed intake conversation; patients with active stimulant misuse are a different conversation altogether.